Regentis Biomaterials Ltd (RGNT) Stock Analysis

$1.180

+0.010 (+0.85%)At close

Loading chart…

High: 1.220
Open: 1.172
VWAP: 1.19
Volume: 23.20K
Mkt Cap: —
Low: 1.160
Amount: 27.53K
EV/EBITDA, TTM: 0.00

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

www.regentis.co.il

AI analysis of Regentis Biomaterials Ltd (RGNT)

Sell

Regentis Biomaterials Ltd is not a good buy right now due to its extremely low RSI of 26.439, indicating oversold conditions, and a staggering year-to-date decline of 82.49%.

Valuation Metrics

The current forward P/E ratio for Regentis Biomaterials Ltd (RGNT) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued

5Y Average P/E

0.00

Current P/E

0.00

Overvalued

0.00

Undervalued

0.00

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Overvalued

0.00

Undervalued

0.00

Events Timeline

2026-10-12 (ET)